Citations (77)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (16)
Maria Dinche Johansen, Thomas Urup, Camilla Bjørnbak Holst, Ib Jarle Christensen, Kirsten Grunnet, Ulrik Lassen, Søren Friis & Hans Skovgaard Poulsen. (2018) Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors. Cancer Investigation 36:9-10, pages 512-519.
Read now
Read now
Anders Toft, Thomas Urup, Ib Jarle Christensen, Signe Regner Michaelsen, Babloo Lukram, Kirsten Grunnet, Michael Kosteljanetz, Vibeke Andrée Larsen, Ulrik Lassen, Helle Broholm & Hans Skovgaard Poulsen. (2018) Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan. Cancer Investigation 36:2, pages 165-174.
Read now
Read now
Stefan-Alexandru Artene, Adina Turcu-Stiolica, Richard Hartley, Marius Eugen Ciurea, Oana Daianu, Corina Brindusa, Oana Alexandru, Ligia Gabriela Tataranu, Stefana Oana Purcaru & Anica Dricu. (2016) Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis. OncoTargets and Therapy 9, pages 6669-6677.
Read now
Read now
Thomas Urup, Rikke Hedegaard Dahlrot, Kirsten Grunnet, Ib Jarle Christensen, Signe Regner Michaelsen, Anders Toft, Vibeke Andrée Larsen, Helle Broholm, Michael Kosteljanetz, Steinbjørn Hansen, Hans Skovgaard Poulsen & Ulrik Lassen. (2016) Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan. Acta Oncologica 55:4, pages 418-422.
Read now
Read now
Omar Abdel-Rahman & Mona Fouad. (2015) Irinotecan-based regimens for recurrent glioblastoma multiform: a systematic review. Expert Review of Neurotherapeutics 15:11, pages 1255-1270.
Read now
Read now
Emilie Le Rhun, Sophie Taillibert & Marc C Chamberlain. (2015) Anaplastic glioma: current treatment and management. Expert Review of Neurotherapeutics 15:6, pages 601-620.
Read now
Read now
Danop Nanegrungsunk, Wimrak Onchan, Nipon Chattipakorn & Siriporn C. Chattipakorn. (2015) Current evidence of temozolomide and bevacizumab in treatment of gliomas. Neurological Research 37:2, pages 167-183.
Read now
Read now
Kenneth F. Hofland, Steinbjørn Hansen, Morten Sorensen, Silke Engelholm, Henrik P. Schultz, Aida Muhic, Kirsten Grunnet, Anders Ask, Junia C. Costa, Charlotte Kristiansen, Carsten Thomsen, Hans Skovgaard Poulsen & Ulrik Lassen. (2014) Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study. Acta Oncologica 53:7, pages 939-944.
Read now
Read now
Mustafa Khasraw, Malaka Ameratunga & Christian Grommes. (2014) Bevacizumab for the treatment of high-grade glioma: an update after Phase III trials. Expert Opinion on Biological Therapy 14:5, pages 729-740.
Read now
Read now
Søren Møller, Kirsten Grunnet, Steinbjørn Hansen, Henrik Schultz, Mats Holmberg, Morten Sorensen, Hans S. Poulsen & Ulrik Lassen. (2012) A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta Oncologica 51:6, pages 797-804.
Read now
Read now
Pol Specenier. (2012) Bevacizumab in glioblastoma multiforme. Expert Review of Anticancer Therapy 12:1, pages 9-18.
Read now
Read now
Jan Nyrop Jakobsen, Benedikte Hasselbalch, Marie-Thérése Stockhausen, Ulrik Lassen & Hans Skovgaard Poulsen. (2011) Irinotecan and bevacizumab in recurrent glioblastoma multiforme. Expert Opinion on Pharmacotherapy 12:5, pages 825-833.
Read now
Read now
Lois A. Lampson. (2011) Monoclonal antibodies in neuro-oncology. mAbs 3:2, pages 153-160.
Read now
Read now
Argirios Moustakas & Teri N Kreisl. (2010) New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab. OncoTargets and Therapy 3, pages 27-38.
Read now
Read now
Valentino Laquintana, Adriana Trapani, Nunzio Denora, Fan Wang, James M Gallo & Giuseppe Trapani. (2009) New strategies to deliver anticancer drugs to brain tumors. Expert Opinion on Drug Delivery 6:10, pages 1017-1032.
Read now
Read now
Hrvoje Miletic, Simone P Niclou, Mikael Johansson & Rolf Bjerkvig. (2009) Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opinion on Therapeutic Targets 13:4, pages 455-468.
Read now
Read now
Articles from other publishers (61)
Jung Hak Kim, Jae Sung Ahn, Dong-Seok Lee, Seok Ho Hong & Hong J. Lee. (2023) Anti-Cancer Effect of Neural Stem Cells Transfected with Carboxylesterase and sTRAIL Genes in Animals with Brain Lesions of Lung Cancer. Pharmaceuticals 16:8, pages 1156.
Crossref
Crossref
Soufyan Annakib, Valérie Rigau, Amélie Darlix, Catherine Gozé, Hugues Duffau, Luc Bauchet, Marta Jarlier & Michel Fabbro. (2023) Bevacizumab in recurrent WHO grades II–III glioma. Frontiers in Oncology 13.
Crossref
Crossref
Herbert B. Newton & Ekokobe Fonkem. 2022. Handbook of Neuro-Oncology Neuroimaging. Handbook of Neuro-Oncology Neuroimaging
9
24
.
Fatma E. El-Khouly, Sophie E. M. Veldhuijzen van Zanten, Marc H. A. Jansen, Dewi P. Bakker, Esther Sanchez Aliaga, N. Harry Hendrikse, W. Peter Vandertop, Dannis G. van Vuurden & Gertjan J. L. Kaspers. (2021) A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma. Journal of Neuro-Oncology 153:2, pages 263-271.
Crossref
Crossref
I. Rouco Axpe, B. Mateos Goñi, L. Zaldumbide Dueñas & E. Fernández-Lomana Idiondo. (2021) Glioblastoma with an unusual presentation: a diagnostic challenge. Neurología (English Edition) 36:3, pages 241-243.
Crossref
Crossref
I. Rouco Axpe, B. Mateos Goñi, L. Zaldumbide Dueñas & E. Fernández-Lomana Idiondo. (2021) Dificultad en el diagnóstico de un glioblastoma de presentación inhabitual. Neurología 36:3, pages 241-243.
Crossref
Crossref
Thomas Urup, Linn Gillberg, Katja Kaastrup, Maya Jeje Schuang Lü, Signe Regner Michaelsen, Vibeke Andrée Larsen, Ib Jarle Christensen, Helle Broholm, Ulrik Lassen, Kirsten Grønbæk & Hans Skovgaard Poulsen. (2020) Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma. Molecular Oncology 14:5, pages 964-973.
Crossref
Crossref
Julian P. Tuazon, Vanessa Castelli, Jea-Young Lee, Giovambattista B. Desideri, Liborio Stuppia, Anna Maria Cimini & Cesar V. Borlongan. 2019. Stem Cells. Stem Cells
79
91
.
Dongyun Zhang & Anthony P. Heaney. 2019. Prolactin Disorders. Prolactin Disorders
219
236
.
Signe R Michaelsen, Mikkel Staberg, Henriette Pedersen, Kamilla E Jensen, Wiktor Majewski, Helle Broholm, Mette K Nedergaard, Christopher Meulengracht, Thomas Urup, Mette Villingshøj, Slávka Lukacova, Jane Skjøth-Rasmussen, Jannick Brennum, Andreas Kjær, Ulrik Lassen, Marie-Thérése Stockhausen, Hans S Poulsen & Petra Hamerlik. (2018) VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance. Neuro-Oncology 20:11, pages 1462-1474.
Crossref
Crossref
Enrico Franceschi, Giuseppe Lamberti, Alexandro Paccapelo, Monica Di Battista, Giovenzio Genestreti, Santino Minichillo, Antonella Mura, Stefania Bartolini, Raffaele Agati & Alba A. Brandes. (2018) Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?. Journal of Neuro-Oncology 139:2, pages 383-388.
Crossref
Crossref
Signe Regner Michaelsen, Thomas Urup, Lars Rønn Olsen, Helle Broholm, Ulrik Lassen & Hans Skovgaard Poulsen. (2018) Molecular profiling of short-term and long-term surviving patients identifies CD34 mRNA level as prognostic for glioblastoma survival. Journal of Neuro-Oncology 137:3, pages 533-542.
Crossref
Crossref
J. N. Jakobsen, T. Urup, K. Grunnet, A. Toft, M. D. Johansen, S. H. Poulsen, I. J. Christensen, A. Muhic & H. S. Poulsen. (2018) Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients. Journal of Neuro-Oncology 137:2, pages 439-446.
Crossref
Crossref
D. Haddad, A. Guha, F. Awan, E.G. Daoud & R. Baliga. 2018. Encyclopedia of Cardiovascular Research and Medicine. Encyclopedia of Cardiovascular Research and Medicine
162
181
.
A. Guha. 2018. Reference Module in Biomedical Sciences. Reference Module in Biomedical Sciences.
Thomas Urup, Line Mærsk Staunstrup, Signe Regner Michaelsen, Kristoffer Vitting-Seerup, Marc Bennedbæk, Anders Toft, Lars Rønn Olsen, Lars Jønson, Shohreh Issazadeh-Navikas, Helle Broholm, Petra Hamerlik, Hans Skovgaard Poulsen & Ulrik Lassen. (2017) Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients. BMC Cancer 17:1.
Crossref
Crossref
Matthew Tipping, Jens Eickhoff & H. Ian Robins. (2017) Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature. Journal of Clinical Neuroscience 44, pages 101-106.
Crossref
Crossref
Oliver Schnell, Jun Thorsteinsdottir, Daniel Felix Fleischmann, Markus Lenski, Wolfgang Abenhardt, Armin Giese, Jörg-Christian Tonn, Claus Belka, Friedrich Wilhelm Kreth & Maximilian Niyazi. (2016) Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma. Journal of Neuro-Oncology 130:3, pages 591-599.
Crossref
Crossref
Thomas Urup, Signe Regner Michaelsen, Lars Rønn Olsen, Anders Toft, Ib Jarle Christensen, Kirsten Grunnet, Ole Winther, Helle Broholm, Michael Kosteljanetz, Shohreh Issazadeh-Navikas, Hans Skovgaard Poulsen & Ulrik Lassen. (2016) Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients. Molecular Oncology 10:8, pages 1160-1168.
Crossref
Crossref
Daniel Ruiz-Sánchez, Irene Iglesias Peinado, Miguel Alaguero-Calero, Alejandro José Sastre-Heres, Benito García Diez & Jaime Peña-Díaz. (2016) Cost-effectiveness analysis of the bevacizumab-irinotecan regimen in the treatment of primary glioblastoma multiforme recurrences. Oncology Letters 12:3, pages 1935-1940.
Crossref
Crossref
Oguz Ozel, Mehmet Kurt, Oguzhan Ozdemir, Jale Bayram, Huseyin Akdeniz & Dogan Koca. (2016) Complete response to bevacizumab plus irinotecan in patients with rapidly progressive GBM: Cases report and literature review. Journal of Oncological Sciences 2:2-3, pages 87-94.
Crossref
Crossref
Michela Buglione, Sara Pedretti, Pietro Luigi Poliani, Roberto Liserre, Stefano Gipponi, Giannantonio Spena, Paolo Borghetti, Ludovica Pegurri, Federica Saiani, Luigi Spiazzi, Giulia Tesini, Chiara Uccelli, Luca Triggiani & Stefano Maria Magrini. (2016) Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: Could a margin reduction be proposed?. Journal of Neuro-Oncology 128:2, pages 303-312.
Crossref
Crossref
Fabian Finkelmeier, Se-Jong You, Oliver Waidmann, Robert Wolff, Stefan Zeuzem, Oliver Bähr & Jörg Trojan. (2015) Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis. Journal of Gastrointestinal Cancer 47:1, pages 82-88.
Crossref
Crossref
ZHIYUN YU, GANG ZHAO, ZHONGHUA ZHANG, YUNQIAN LI, YONG CHEN, NAN WANG, ZHONGYING ZHAO & GUIFANG XIE. (2016) Efficacy and safety of bevacizumab for the treatment of glioblastoma. Experimental and Therapeutic Medicine 11:2, pages 371-380.
Crossref
Crossref
Maximilian Niyazi, Patrick N. Harter, Elke Hattingen, Maya Rottler, Louisa von Baumgarten, Martin Proescholdt, Claus Belka, Kirsten Lauber & Michel Mittelbronn. (2015) Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?. Oncotarget 7:3, pages 2313-2328.
Crossref
Crossref
Herbert B. Newton. 2016. Handbook of Neuro-Oncology Neuroimaging. Handbook of Neuro-Oncology Neuroimaging
9
22
.
Zhiguang Liu, Guanqun Zhang, Liang Zhu, Jiangbo Wang, Dongbo Liu, Lifei Lian, Jianlin Liu, Tianbao Lai & Xiaorong Zhuang. (2015) Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme. BioMed Research International 2015, pages 1-8.
Crossref
Crossref
Herbert B. Newton & Jose J. Otero. 2015. Epilepsy and Brain Tumors. Epilepsy and Brain Tumors
11
28
.
Jeffrey J. Olson, Lakshmi Nayak, D. Ryan Ormond, Patrick Y. Wen, Steven N. Kalkanis & Timothy Charles Ryken. (2014) The role of targeted therapies in the management of progressive glioblastoma. Journal of Neuro-Oncology 118:3, pages 557-599.
Crossref
Crossref
Benedikt Wiestler, Alexander Radbruch, Matthias Osswald, Stephanie E. Combs, Christine Jungk, Frank Winkler, Martin Bendszus, Andreas Unterberg, Michael Platten, Wolfgang Wick & Antje Wick. (2014) Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant glioma. Journal of Neuro-Oncology 117:1, pages 85-92.
Crossref
Crossref
G. Simonetti, E. Trevisan, A. Silvani, P. Gaviani, A. Botturi, E. Lamperti, D. Beecher, L. Bertero, C. Bosa & A. Salmaggi. (2013) Safety of bevacizumab in patients with malignant gliomas: a systematic review. Neurological Sciences 35:1, pages 83-89.
Crossref
Crossref
Signe Regner Michaelsen, Ib Jarle Christensen, Kirsten Grunnet, Marie-Thérése Stockhausen, Helle Broholm, Michael Kosteljanetz & Hans Skovgaard Poulsen. (2013) Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution. BMC Cancer 13:1.
Crossref
Crossref
S H Hong, H J Lee, J An, I Lim, C Borlongan, K S Aboody & S U Kim. (2013) Human neural stem cells expressing carboxyl esterase target and inhibit tumor growth of lung cancer brain metastases. Cancer Gene Therapy 20:12, pages 678-682.
Crossref
Crossref
Solmaz Sahebjam, Evgenia Garoufalis, Marie-Christine Guiot, Thierry Muanza, Rolando Del Maestro, Kevin Petrecca, Rajesh Sharma & Petr Kavan. (2014) Bevacizumab Use for Recurrent High-Grade Glioma at McGill University Hospital. Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 40:2, pages 241-246.
Crossref
Crossref
Miguel J. Gil-GilCarlos MesiaMontserrat ReyJordi Bruna. (2013) Bevacizumab for the Treatment of Glioblastoma. Clinical Medicine Insights: Oncology 7, pages CMO.S8503.
Crossref
Crossref
Cécile Thirant, Julie Gavard, Marie‐Pierre Junier & Hervé Chneiweiss. (2013) Critical multiple angiogenic factors secreted by glioblastoma stem‐like cells underline the need for combinatorial anti‐angiogenic therapeutic strategies. PROTEOMICS – Clinical Applications 7:1-2, pages 79-90.
Crossref
Crossref
Guobin Zhang, Shengyue Huang & Zhongcheng Wang. (2012) A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme. Journal of Clinical Neuroscience 19:12, pages 1636-1640.
Crossref
Crossref
DANIEL RUIZ-SÁNCHEZ, MIGUEL ALAGUERO CALERO, ALEJANDRO JOSÉ SASTRE-HERES, MARÍA TERESA IGLESIAS GARCÍA, MIGUEL ANGEL CALLEJA HERNANDEZ, FERNANDO MARTÍNEZ MARTINEZ & JAIME PEÑA-DÍAZ. (2012) Effectiveness of the bevacizumab-irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second-line treatments without this regimen. Oncology Letters 4:5, pages 1114-1118.
Crossref
Crossref
Miguel J. Gil, Ramón de las Peñas, Gaspar Reynés, Carme Balañá, Pedro Peréz-Segura, Adelaida García-Velasco, Carlos Mesia, Óscar Gallego, Concepción Fernández-Chacón, María Martínez-García, Ana Herrero, Raquel Andrés, Manuel Benavides, Teresa Quintanar & Xavier Pérez-Martin. (2012) Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anti-Cancer Drugs 23:6, pages 659-665.
Crossref
Crossref
Han Shen & Kerrie L. McDonald. (2012) The Complexities of Resistance to Bevacizumab. Journal of Cancer Therapy 03:05, pages 491-503.
Crossref
Crossref
Maximilian Niyazi, Ute Ganswindt, Silke Birgit Schwarz, Friedrich-Wilhelm Kreth, Jörg-Christian Tonn, Julia Geisler, Christian la Fougère, Lorenz Ertl, Jennifer Linn, Axel Siefert & Claus Belka. (2012) Irradiation and Bevacizumab in High-Grade Glioma Retreatment Settings. International Journal of Radiation Oncology*Biology*Physics 82:1, pages 67-76.
Crossref
Crossref
Marie-Thérése Stockhausen, Karina Kristoffersen & Hans Skovgaard Poulsen. 2012. Notch Signaling in Embryology and Cancer. Notch Signaling in Embryology and Cancer
289
304
.
Kathryn Beal, Lauren E Abrey & Philip H Gutin. (2011) Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches. Radiation Oncology 6:1.
Crossref
Crossref
Ho Jun Seol, Juyoun Jin, Dong-Ho Seong, Kyeung Min Joo, Wonyoung Kang, Heekyoung Yang, Jandi Kim, Chul Soo Shin, Yonghyun Kim, Kang Ho Kim, Doo-Sik Kong, Jung-II Lee, Karen S. Aboody, Hong Jun Lee, Seung U. Kim & Do-Hyun Nam. (2011) Genetically engineered human neural stem cells with rabbit carboxyl esterase can target brain metastasis from breast cancer. Cancer Letters 311:2, pages 152-159.
Crossref
Crossref
Seema Nagpal, Griffith Harsh & Lawrence Recht. (2011) Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma. Chemotherapy Research and Practice 2011, pages 1-6.
Crossref
Crossref
Jennifer C. Kesselheim, Andrew D. NordenPatrick Y. WenSteven Joffe. (2011) Discontinuing Bevacizumab in Patients with Glioblastoma: An Ethical Analysis. The Oncologist 16:10, pages 1435-1439.
Crossref
Crossref
T. N. Kreisl, W. Zhang, Y. Odia, J. H. Shih, J. A. Butman, D. Hammoud, F. M. Iwamoto, J. Sul & H. A. Fine. (2011) A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro-Oncology 13:10, pages 1143-1150.
Crossref
Crossref
Roger Henriksson, Thomas Asklund & Hans Skovgaard Poulsen. (2011) Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. Journal of Neuro-Oncology 104:3, pages 639-646.
Crossref
Crossref
Athanassios P. Kyritsis & Victor A. Levin. (2011) An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting. Cancer Chemotherapy and Pharmacology 67:5, pages 971-983.
Crossref
Crossref
L.J. Murray, C.H. Bridgewater & D. Levy. (2011) Carboplatin Chemotherapy in Patients with Recurrent High-grade Glioma. Clinical Oncology 23:1, pages 55-61.
Crossref
Crossref
Maximilian Niyazi, Axel Siefert, Silke Birgit Schwarz, Ute Ganswindt, Friedrich-Wilhelm Kreth, Jörg-Christian Tonn & Claus Belka. (2011) Therapeutic options for recurrent malignant glioma. Radiotherapy and Oncology 98:1, pages 1-14.
Crossref
Crossref
Steven Brem & Eric T. Wong. 2011. Youmans Neurological Surgery. Youmans Neurological Surgery
1151
1171
.
Benedikte Hasselbalch, Ulrik Lassen & Hans Skovgaard Poulsen. 2011. Tumors of the Central Nervous System, Volume 2. Tumors of the Central Nervous System, Volume 2
289
299
.
Tao Xu, Juxiang Chen, Yicheng Lu & Johannes EA Wolff. (2010) Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer 10:1.
Crossref
Crossref
Benedikte Hasselbalch, Jesper Grau Eriksen, Helle Broholm, Ib Jarle Christensen, Kirsten Grunnet, Michael R. Horsman, Hans Skovgaard Poulsen, Marie‐Thérése Stockhausen & Ulrik Lassen. (2010) Prospective evaluation of angiogenic, hypoxic and EGFR‐related biomarkers in recurrent glioblastoma multiforme treated with cetuximab, bevacizumab and irinotecan. APMIS 118:8, pages 585-594.
Crossref
Crossref
J.J.C. Verhoeff, C. Lavini, M.E. van Linde, L.J.A. Stalpers, C.B.L.M. Majoie, J.C. Reijneveld, W.R. van Furth & D.J. Richel. (2010) Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Annals of Oncology 21:8, pages 1723-1727.
Crossref
Crossref
James R. PerryKarl BélangerWarren P. MasonDorcas FultonPetr KavanJacob EasawClaude ShieldsSarah KirbyDavid R. MacdonaldDavid D. EisenstatBrian ThiessenPeter ForsythJean-François Pouliot. (2010) Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study. Journal of Clinical Oncology 28:12, pages 2051-2057.
Crossref
Crossref
M.-T. Stockhausen, K. Kristoffersen & H. S. Poulsen. (2009) The functional role of Notch signaling in human gliomas. Neuro-Oncology 12:2, pages 199-211.
Crossref
Crossref
Joost JC Verhoeff, Olaf van Tellingen, An Claes, Lukas JA Stalpers, Myra E van Linde, Dirk J Richel, William PJ Leenders & Wouter R van Furth. (2009) Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 9:1.
Crossref
Crossref
Andrew D. Norden, Jan Drappatz & Patrick Y. Wen. (2009) Antiangiogenic therapies for high-grade glioma. Nature Reviews Neurology 5:11, pages 610-620.
Crossref
Crossref
Herbert B. Newton. (2009) Bevacizumab: Review of Development, Pharmacology, and Application to Brain Tumors. Clinical Medicine. Therapeutics 1, pages CMT.S2042.
Crossref
Crossref